diversification.com

GMAB

Companies
NASDAQ
Genmab A/S Sponsored ADR
Health Care
OverviewNewsRisk & CorrelationForecasts
Price Chart
Overview

About GMAB

Genmab A/S is a Danish biotechnology company, founded in February 1999 by Florian Schönharting, at the time managing director of BankInvest Biomedical venture fund.

Market Cap
$17.8B
Volume
38.0M
Avg. Volume
31.7M
P/E Ratio
14.521429
Dividend Yield
0.00%
Employees
1.5K

Company Information

Exchange
NASDAQ
Sector
Health Care
Industry
Biotechnology
Latest News for GMAB

Japanese Drug Regulator Approves Genmab Cancer Drug For Patients With Advanced Cervical Cancer

March 27, 2025

Should Value Investors Buy Genmab (GMAB) Stock?

April 16, 2025
Risk & Correlation Analysis
Market Correlation
0.82
Moderate Correlation
Volatility
Medium (0.36)
Relative to market

Macro Factor Sensitivities

Interest Rates
Low Sensitivity
Inflation
High Sensitivity
GDP Growth
Medium Sensitivity
Liquidity
Medium Sensitivity
Commodity Prices
Low Sensitivity
Credit Quality
High Sensitivity
Portfolio Impact
Forecasts & Predictions

Premium Forecasts

Get AI-powered price predictions, technical analysis, and market forecasts for GMAB.

1-Month Target
$XXX.XX
+X.X% Potential
3-Month Target
$XXX.XX
+X.X% Potential
12-Month Target
$XXX.XX
+X.X% Potential

Technical Analysis

Based on technical indicators and chart patterns, GMAB shows...

AI Sentiment Analysis

Market sentiment analysis indicates...

Key Statistics
Market Cap$17.8B
Volume38.0M
P/E Ratio14.52
Dividend Yield0.00%
Important Dates
Next Dividend
Next Earnings
August 6, 2025
Related Securities
IBB
iShares Biotechnology ETF
REGN
Regeneron Pharmaceuticals, Inc.
VRTX
Vertex Pharmaceuticals Inc.
ILMN
Illumina, Inc.

PortfolioPilot Analysis

Get AI-powered insights on how GMAB fits into your investment strategy and portfolio diversification.

Pricing info last updated June 18, 2025 (after market close)Other info last updated April 2, 2025